Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(denileukin diftitox)
267 results
  • Critical Issues in the Development of Immunotoxins for Anticancer Therapy. [Review]
    J Pharm Sci 2019Kim JS, Jun SY, Kim YS
  • Immunotoxins (ITs) are attractive anticancer modalities aimed at cancer-specific delivery of highly potent cytotoxic protein toxins. An IT consists of a targeting domain (an antibody, cytokine, or another cell-binding protein) chemically conjugated or recombinantly fused to a highly cytotoxic payload (a bacterial and plant toxin or human cytotoxic protein). The mode of action of ITs is killing de…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Denileukin Diftitox [BOOK]
    National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Denileukin diftitox is a recombinant fusion protein of human interleukin-2 (IL-2) attached to diphtheria toxin fragments A and B that is used as an antineoplastic agent to treat cutaneous T cell lymphomas that express IL-2 receptors. High doses of denileukin diftitox can cause mild-to-moderate elevations in serum enzymes and bilirubin, but rarely result in clinically significant acute liver injur…
  • Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy. [Journal Article]
    Immunotherapy 2019; 11(13):1117-1128Kumar P, Kumar A, … Bishai W
  • T regulatory cells (Tregs) are an important T cell population for immune tolerance, prevention of autoimmune diseases and inhibition of antitumor immunity. The tumor-promoting role played by Tregs in cancer has prompted numerous approaches to develop immunotherapeutics targeting Tregs. One approach to depletion of Treg cells is retargeting the highly potent cytotoxic activity of bacterial toxins.…
  • Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. [Review]
    Front Med (Lausanne) 2019; 6:116Oka T, Miyagaki T
  • Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin. On the other hand, in some cases, patients show skin tumors or erythroderma followed by lymph node involvement and rarely visceral organ involvement. SS is a rare, aggressive cutan…
  • Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome. [Review]
    Best Pract Res Clin Haematol 2018; 31(3):322-335Prince HM, Querfeld C
  • Novel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab…
New Search Next